Integrase-defective lentiviral-vector-based vaccine: A new vector for induction of T cell immunity

Expert Opinion on Biological Therapy

Volumn 11, Issue 6, 2011, Pages 739-750

  Negri, Donatella Rm ^a   Michelini, Zuleika ^a   Bona, Roberta ^a   Blasi, Maria ^a   Filati, Piero ^a   Leone, Pasqualina ^a   Rossi, Alessandra ^a   Franco, Marina ^a   Cara, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV 1; integrase; integrase inhibitors; lentiviral vector; T cell immunity; vaccine

Indexed keywords

ELVITEGRAVIR; EXTRACHROMOSOMAL DNA; GAG PROTEIN; GLYCOPROTEIN GP 100; HEPATITIS B SURFACE ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN; INFLUENZA MATRIX M1 PROTEIN; INTEGRASE; INTEGRASE DEFICIENT LENTIVIRUS VECTOR; INTEGRASE INHIBITOR; LENTIVIRUS VECTOR; OVALBUMIN; PROTEIN P51; RALTEGRAVIR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; WEST NILE VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; LENTIVIRUS INFECTION; LONG TERMINAL REPEAT; LOW DRUG DOSE; NONHUMAN; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS IMMUNITY;

GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INTEGRASES; LENTIVIRUS; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PRIMATES;

EID: 79955834798     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.571670     Document Type: Review

References (98)

1. Vidor E. Evaluation of the persistence of vaccine-induced protection with human vaccines. J Comp Pathol 2010;142(Suppl 1):96-101
2. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503
3. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010;22:358-66
4. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004;101:14567-71
5. Relph K, Harrington K, Pandha H. Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 2004;329:839-42 (Pubitemid 39388412)
6. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther 2004;10:616-29 (Pubitemid 39272851)
7. Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 2004;4:861-8 (Pubitemid 38843223)
8. Voltan R, Robert-Guroff M. Live recombinant vectors for AIDS vaccine development. Curr Mol Med 2003;3:273-84 (Pubitemid 36443225)
9. Beignon AS, Mollier K, Liard C, et al. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 2009;83:10963-74
10. Arya SK, Cho JE, Chang SH. HIV-2 vectors. Methods Mol Biol 2003;229:219-31
11. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7 (Pubitemid 26119138)
12. Negre D, Cosset FL. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 2002;84:1161-71 (Pubitemid 36253742)
13. Barraza RA, Poeschla EM. Human gene therapy vectors derived from feline lentiviruses. Vet Immunol Immunopathol 2008;123:23-31
14. Molina RP, Matukonis M, Paszkiet B, et al. Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector. Virology 2002;304:10-23 (Pubitemid 36062828)
15. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999;6:1808-18 (Pubitemid 29531276)
16. Mselli-Lakhal L, Guiguen F, Greenland T, et al. Gene transfer system derived from the caprine arthritis-encephalitis lentivirus. J Virol Methods 2006;136:177-84 (Pubitemid 44051590)
17. Metharom P, Takyar S, Xia HH, et al. Novel bovine lentiviral vectors based on Jembrana disease virus. J Gene Med 2000;2:176-85
18. Berkowitz RD, Ilves H, Plavec I, et al. Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 2001;279:116-29 (Pubitemid 34162554)
19. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005;5:387-98 (Pubitemid 41052430)
20. Watson DJ, Kobinger GP, Passini MA, et al. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002;5:528-37 (Pubitemid 34546082)
21. Miyoshi H, Takahashi M, Gage FH, et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997;94:10319-23 (Pubitemid 27407039)
22. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17:314-17 (Pubitemid 27475995)
23. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol Ther 2007;15:445-56
24. Arce F, Rowe HM, Chain B, et al. Lentiviral vectors transducer proliferating dendritic cell precursor leading to persistent antigen presentation and immunization. Mol Ther 2009;17:1643-50
25. Schroers R, Sinha I, Segall H, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 2000;1:171-9
26. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004;2(12):e423
27. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004;2(8):e234
28. Couzin J, Kaiser J. Gene Therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 2005;307:1028 (Pubitemid 40262084)
29. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2- associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-19 (Pubitemid 37296260)
30. Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007;110:1770-8 (Pubitemid 47443887)
31. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-96 (Pubitemid 43882120)
32. Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 2011: published online 19 January 2011, doi:10.1089/ hum.2010.233
33. Hu B, Tai A, Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011;239:45-61
34. Gene Therapy Clinical Trials Worldwide. Hoboken, NJ: John Wiley and Sons, 2007. Available from: . co.uk/genmed/clinical/Updated Jun 2010 [Last accessed 10March 2011]
35. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-4 (Pubitemid 32448333)
36. Cara A, Reitz MS Jr. New insight on the role of extrachromosomal retroviral DNA. Leukemia 1997;11:1395-9 (Pubitemid 27404377)
37. Cara A, Klotman ME. Retroviral E-DNA: persistence and gene expression in nondividing immune cells. J Leukoc Biol 2006;80:1013-17 (Pubitemid 44646307)
38. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009;17:1316-32
39. Vargas J Jr, Gusella GL, Najfeld V, et al. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004;15:361-72 (Pubitemid 38469778)
40. Lu R, Nakajima N, Hofmann W, et al. Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol 2004;78:658-68 (Pubitemid 38067587)
41. Daelemans D, Lu R, De Clercq E, et al. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J Virol 2007;81:4381-5 (Pubitemid 46586937)
42. Vargas J Jr, Klotman ME, Cara A. Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. Antivir Res 2008;80:288-94
43. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12:348-53 (Pubitemid 43355085)
44. Apolonia L, Waddington SN, Fernandes C, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007;15:1947-54 (Pubitemid 350011734)
45. Bayer M, Kantor B, Cockrell A, et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 2008;16:1968-76
46. Saenz DT, Loewen N, Peretz M, et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004;78:2906-20 (Pubitemid 38314348)
47. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006;103:17684-9 (Pubitemid 44852220)
48. Rahim AA, Wong A, Howe SJ, et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 2009;16:509-20
49. Negri DR, Michelini Z, Cara A. Toward integrase defective lentiviral vectors for genetic immunization. Curr HIV Res 2010;8:274-81
50. Coutant F, Frenkiel MP, Despres P, et al. Protective antiviral immunity conferred by a nonintegrative lentiviral vector based vaccine. PLoS One 2008;3:e3973
51. Karwacz K, Mukherjee S, Apolonia L, et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009;83:3094-103
52. Negri DR, Michelini Z, Baroncelli S, et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007;15:1716-23 (Pubitemid 47289016)
53. Hu B, Yang H, Dai B, et al. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 2009;20:1652-64
54. Michelini Z, Negri DR, Baroncelli S, et al. Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine 2009;27:4622-9
55. Hu B, Dai B, Wang P. Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 2010;28:6675-83
56. Negri DR, Michelini Z, Baroncelli S, et al. Nonintegrating lentiviral vector-based vaccine efficiently induces functional and persistent CD8+ T cell responses in mice. J Biomed Biotechnol 2010;534501: published online 19 May2010, doi: 10.1155/2010/534501
57. Negri DR, Bona R, Michelini Z, et al. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8+ T cells. Hum Gene Ther 2010;21:1029-35
58. Poon B, Chen IS. Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol 2003;77:3962-72 (Pubitemid 36350937)
59. Grandchamp N, Henriot D, Philippe S, et al. Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors. Genet Vaccin Ther 2011;9:1
60. Froelich S, Tai A, Wang P. Lentiviral vectors for immune cells targeting. Immunopharmacol Immunotoxicol 2010;32:208-18
61. Berger G, Goujon C, Darlix JL, et al. SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther 2009;16:159-63
62. Goujon C, Riviere L, Jarrosson-Wuilleme L, et al. SIVSM/ HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007;4:2
63. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-58 (Pubitemid 43361590)
64. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-23
65. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11(Suppl 4):S45-53 (Pubitemid 40562303)
66. Armstrong ME, Lavelle EC, Loscher CE, et al. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis 2005;192:1628-33 (Pubitemid 41504699)
67. Lemiale F, Kong WP, Akyurek LM, et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003;77:10078-87 (Pubitemid 37122089)
68. Mutsch M, Zhou W, Rhodes P, et al. N Engl J Med 2004;350:896-903
69. Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009;4(9):e6999
70. Zhu Q, Thomson CW, Rosenthal KL, et al. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol 2008;1:78-88
71. Durham SR. Sublingual immunotherapy: what have we learnt from the 'big trials'?. Curr Opin Allergy Clin Immunol 2008;8:577-84
72. Song JH, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008;105:1644-9 (Pubitemid 351346568)
73. Cuburu N, Kweon MN, Song JK, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007;25:8598-610 (Pubitemid 350192038)
74. Negri DR, Riccomi A, Pinto D, et al. Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 2010;28:4175-80
75. Sinn PL, Arias AC, Brogden KA, et al. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 2008;82:10684-92 (Pubitemid 352691165)
76. Kremer KL, Dunning KR, Parson DW, et al. Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors. J Gene Med 2007;9:362-8 (Pubitemid 46796582)
77. Copreni E, Penzo M, Carrabino S, et al. Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis.Gene Ther 2004;11(Suppl 1):S67-75
78. Hashimoto D, Nagata T, Uchijima M, et al. Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific CD8+ T-cell responses in the lung. Vaccine 2008;26:5095-100
79. Sinn PL, Burnight ER, Hickey MA, et al. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005;79:12818-27 (Pubitemid 41433201)
80. Rowe HM, Lopes L, Brown N, et al. Expression of vFLIP in a lentiviral vaccine vector activates NF-kappaB, matures dendritic cells, and increases CD8+ T-cell responses. J Virol 2009;83:1555-62
81. Pluymers W, De Clercq E, Debyser Z. HIV-1 integration as a target for antiretroviral therapy: a review. Curr Drug Targets Infect Disord 2001;1:133-49
82. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008;51:5843-55
83. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009;10:190-200
84. Ojwang JO, Buckheit RW, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995;39:2426-35
85. Hazuda D J, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50 (Pubitemid 30070911)
86. Vandegraaff N, Kumar R, Hocking H, et al. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother 2001;45:2510-16 (Pubitemid 32801903)
87. Nair V. HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 2002;12:179-93 (Pubitemid 34516949)
88. Svarovskaia E S, Barr R, Zhang X, et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-longterminal-repeat-circle junctions. J Virol 2004;78:3210-22 (Pubitemid 38568261)
89. Bona R, Andreotti M, Buffa V, et al. Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds. Antimicrob Agents Chemother 2006;50:3407-17 (Pubitemid 44527517)
90. Michelini Z, Galluzzo CM, Negri DR, et al. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. J Virol Methods 2010;168:272-6
91. Wu Y, Marsh JW. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003;77:10376-82 (Pubitemid 37129681)
92. Gillim-Ross L, Cara A, Klotman ME. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. Viral Immunol 2005;18:190-6 (Pubitemid 40586456)
93. Zheng Y, Ourmanov I, Hirsch VM. Persistent transcription of a nonintegrating mutant of simian immunodeficiency virus in rhesus macrophages. Virology 2008;372:291-9 (Pubitemid 351273751)
94. Kelly J, Beddall MH, Yu D, et al. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008;372:300-12 (Pubitemid 351273752)
95. Gillim-Ross L, Cara A, Klotman ME. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. J Gen Virol 2005;86:765-71 (Pubitemid 40331257)
96. Poon B, Chang MA, Chen IS. Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA. J Virol 2007;81:10515-23 (Pubitemid 47463324)
97. Sloan RD, Donahue DA, Kuhl BD, et al. Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology 2010;7:44
98. Kantor B, Ma H, Webster-Cyriaque J, et al. Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implication for HIV infection. Proc Natl Acad Sci USA 2009;106:18786-91